Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.00%
)
US TECH 100
28,325.40
(
-1.62%
)
Dow Jones
50,063.46
(
0.00%
)
Brent Oil
105.53
(
1.29%
)
Bitcoin
80,072.38
(
-1.21%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jbog

Send PM Follow Ignore
Followers 64
Posts 11880
Boards Moderated 0
Alias Born 07/16/2006

jbog

Re: DewDiligence post# 119748

Tuesday, 05/10/2011 2:00:37 PM

Tuesday, May 10, 2011 2:00:37 PM

Post# of 257566

Woodcock said that if a biotech company develops a longer-lasting version of a drug, or otherwise alters an existing molecule to improve efficacy of safety, it would be considered a new molecule, with a new 12-year exclusivity.



This seems like it will open a new bag of worms. Betterbiosimilar.

I'm wondering how they would treat something like Lilly's humanized egfr versus the chimeric cetuximab?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today